Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Purchase Of Cell Genesys Shows Confidence In Gene Therapy Future

Executive Summary

Genzyme's $350 mil. acquisition of Cell Genesys represents a vote of confidence in gene therapy after concerns about the death of a clinical trial subject.

You may also be interested in...



TKT Hemophilia Gene Therapy Trial Halted Despite No Evidence Of Problems

The suspension of Transkaryotic Therapies' gene therapy trial at Beth Israel Deaconess Medical Center could signal the beginning of a trend of gene therapy trial suspensions as a cautionary measure even if the study shows no sign of problems.

TKT Hemophilia Gene Therapy Trial Halted Despite No Evidence Of Problems

The suspension of Transkaryotic Therapies' gene therapy trial at Beth Israel Deaconess Medical Center could signal the beginning of a trend of gene therapy trial suspensions as a cautionary measure even if the study shows no sign of problems.

Vical Is Vital On Wall Street After Adenoviral Vector Problems

Vical's "naked DNA" vectorless gene therapy technology helped the company outstrip a strong market for biotech stocks and post a 50% gain for the month of November.

Related Content

UsernamePublicRestriction

Register

PS035045

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel